HIMALAYA

NCT03298451 📎

Regimen

Experimental
tremelimumab 300 mg x1 + durvalumab 1500 mg Q4W (STRIDE); durvalumab monotherapy
Control
sorafenib

Population

Unresectable hepatocellular carcinoma, no prior systemic therapy

Key finding

STRIDE mOS 16.43 vs sorafenib 13.77 mo (HR 0.78, 96.02% CI 0.65-0.93, p=0.0035); 36-mo OS 30.7% vs 20.2%; durva mono OS 16.56 mo (HR 0.86, noninferior); PFS not significantly different among arms; etiology HBV 31%, HCV 27%, non-viral 41% (approximately equal across regions)

Source: PMID 38319892

Timeline

    Guideline citations

    • NCCN HCC (p.67)